Código QR (código de barras bidimensional)

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinomaResearch in context

Summary: Background: The prognosis for patients with poorly-differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC) is poor. A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy with no standard second-line (2L) treatment. Methods: Patient...

Fuld beskrivelse

Na minha lista:
Principais autores: Mairéad G. McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jonathan Wadsley, Carys Morgan, Lucy R. Wall, Ian Chau, Nick Reed, Debashis Sarker, Jane Margetts, Daniel Krell, Judith Cave, Sharmila Sothi, Alan Anthoney, Christopher Bell, Alkesh Patel, Jamie B. Oughton, David A. Cairns, Wasat Mansoor, Angela Lamarca, Richard A. Hubner, Juan W. Valle
Format: Artigo
Sprog:Inglês
Udgivet: Elsevier 2023-06-01
Serier:EClinicalMedicine
Fag:
Neuroendocrine carcinoma
Second-line treatment
Liposomal irinotecan
Docetaxel
Quality of life
Online adgang:http://www.sciencedirect.com/science/article/pii/S258953702300192X
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker